These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19884908)

  • 1. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
    Romaine SP; Bailey KM; Hall AS; Balmforth AJ
    Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
    Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
    J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
    Hu M; Tomlinson B
    Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
    Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
    Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
    Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
    Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
    Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
    Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnic differences in statin disposition.
    Tirona RG
    Clin Pharmacol Ther; 2005 Oct; 78(4):311-6. PubMed ID: 16198649
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
    Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
    Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs].
    Ieiri I; Higuchi S
    Yakugaku Zasshi; 2009 Feb; 129(2):231-5. PubMed ID: 19182452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
    Sui SM; Wen JH; Li XH; Xiong YQ
    Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
    Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
    Kivistö KT; Niemi M
    Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
    de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
    Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.